Characteristics | Probiotic | Placebo | RR | 95% CI | p Value |
---|---|---|---|---|---|
1000–1500 g | n=107 | n=97 | |||
Death or NEC, n (%) | 5 (4.7) | 3 (3.1) | 0.65 | 0.15 to 2.79 | 0.41 |
NEC stage ≥2, n (%) | 3 (2.8) | 1 (1) | 0.36 | 0.03 to 3.53 | 0.34 |
Death attributable to NEC, n (%) | 1 (0.93) | 1 (1) | 1.1 | 0.06 to 17.8 | 0.94 |
Death attributable not to NEC, n (%) | 3 (2.8) | 2 (2.1) | 0.73 | 0.11 to 4.46 | 0.73 |
<1000 g | n=93 | n=103 | |||
Death or NEC, n (%) | 15 (16.1) | 24 (23.3) | 1.58 | 0.77 to 3.23 | 0.14 |
NEC stage ≥2, n (%) | 5 (5.4) | 9 (8.7) | 1.68 | 0.54 to 5.22 | 0.26 |
Death attributable to NEC, n (%) | 2 (2.2) | 3 (2.9) | 1.36 | 0.22 to 8.35 | 0.73 |
Death attributable not to NEC, n (%) | 9 (9.7) | 14 (13.6) | 1.46 | 0.6 to 3.57 | 0.39 |
NEC, necrotising enterocolitis; RR, relative risk.